The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome - PubMed (original) (raw)

Clinical Trial

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome

Jonathan M Meyer et al. Schizophr Res. 2005.

Abstract

The metabolic syndrome (MS) is highly prevalent among patients with schizophrenia (current estimates 35-40%), yet no data exist on the correlation of this diagnosis with illness severity, neurocognitive or quality of life measures in this population.

Methods: Using baseline data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial, assignment of MS status was performed using an updated definition derived from the National Cholesterol Education Program (NCEP) criteria. Those with and without MS were compared on the basis of primary and secondary variables of interest from baseline data encompassing psychiatric, neurocognitive and quality of life measures.

Results: Of 1460 subjects enrolled at baseline, MS status could be reliably assigned for 1231 subjects, with a prevalence of 35.8% using the NCEP derived criteria. After adjustment for age, gender, race, ethnicity and site variance, those with MS rated themselves significantly lower on physical health by SF-12 (p < .001), and scored higher on somatic preoccupation (PANSS item G1) (p = .03). There were no significant differences between the two cohorts on measures of symptom severity, depression, quality of life, neurocognition, or self-rated mental health. Neither years of antipsychotic exposure nor alcohol usage were significant predictors of MS status when adjusted for age, gender, race, and ethnicity.

Conclusions: The metabolic syndrome is highly prevalent in this large cohort of schizophrenia patients and is strongly associated with a poor self-rating of physical health and increased somatic preoccupation. These results underscore the need for mental health practitioners to take an active role in the health monitoring of patients with schizophrenia to minimize the impact of medical comorbidity on long-term mortality and on daily functioning. Outcomes data from CATIE will provide important information on the metabolic and clinical impact of antipsychotic treatment for those subjects with MS and other medical comorbidities.

PubMed Disclaimer

Cited by

Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.
Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Suzuki Y, Someya T. Sugawara N, et al. PLoS One. 2014 Jan 23;9(1):e86826. doi: 10.1371/journal.pone.0086826. eCollection 2014. PLoS One. 2014. PMID: 24466260 Free PMC article.
The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.
Papanastasiou E. Papanastasiou E. Ther Adv Psychopharmacol. 2013 Feb;3(1):33-51. doi: 10.1177/2045125312464385. Ther Adv Psychopharmacol. 2013. PMID: 23983991 Free PMC article.
A widening longevity gap between people with schizophrenia and general population: A literature review and call for action.
Lee EE, Liu J, Tu X, Palmer BW, Eyler LT, Jeste DV. Lee EE, et al. Schizophr Res. 2018 Jun;196:9-13. doi: 10.1016/j.schres.2017.09.005. Epub 2017 Sep 28. Schizophr Res. 2018. PMID: 28964652 Free PMC article.
Estrogens in schizophrenia: progress, current challenges and opportunities.
Brand BA, de Boer JN, Sommer IEC. Brand BA, et al. Curr Opin Psychiatry. 2021 May 1;34(3):228-237. doi: 10.1097/YCO.0000000000000699. Curr Opin Psychiatry. 2021. PMID: 33560022 Free PMC article. Review.
Ziprasidone hydrocloride: what role in the management of schizophrenia?
Mattei C, Rapagnani MP, Stahl SM. Mattei C, et al. J Cent Nerv Syst Dis. 2011 Feb 15;3:1-16. doi: 10.4137/JCNSD.S4138. Print 2011. J Cent Nerv Syst Dis. 2011. PMID: 23861634 Free PMC article.

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome - PubMed (original) (raw)